Ocedurenone

2023 - 10 - 16

Post cover
Image courtesy of "Forbes"

Novo Nordisk Buys Hypertension Drug Ocedurenone For $1.3 ... (Forbes)

The Danish firm said the drug has “best-in-class potential” for treating uncontrolled hypertension.

Post cover
Image courtesy of "Goodwin Procter"

KBP Biosciences Announces Sale of Ocedurenone to Novo Nordisk ... (Goodwin Procter)

Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial ...

Post cover
Image courtesy of "GlobeNewswire"

Novo Nordisk to acquire ocedurenone for uncontrolled hypertension ... (GlobeNewswire)

Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire.

Post cover
Image courtesy of "Reuters"

Novo Nordisk in $1.3 bln deal to buy hypertension drug (Reuters)

Novo Nordisk has agreed to buy ocedurenone, a drug for uncontrolled hypertension with potential application in cardiovascular and kidney disease, ...

Novo Nordisk To Buy Hypertension Drug Ocedurenone From KBP ... (Nasdaq)

(RTTNews) - Biopharmaceutical major Novo Nordisk A/S (NVO) announced on Monday that it has agreed to acquire ocedurenone for uncontrolled hypertension from ...

Post cover
Image courtesy of "BioSpace"

Novo in $1.3B Deal Buys Late-Stage Hypertension Drug from ... (BioSpace)

The Danish pharma announced Monday that it is buying a Phase III hypertension candidate from Singapore-based KBP Biosciences. It is Novo Nordisk's third ...

Post cover
Image courtesy of "FierceBiotech"

Novo Nordisk buys rival to Bayer's Kerendia in $1.3B deal (FierceBiotech)

Novo Nordisk has agreed to pay up to $1.3 billion for KBP Biosciences' phase 3 challenger to Bayer's chronic kidney disease drug Kerendia.

Post cover
Image courtesy of "PMLiVE"

Novo Nordisk to buy KBP's hypertension drug ocedurenone for up to ... (PMLiVE)

Novo Nordisk has agreed to acquire ocedurenone, a drug for uncontrolled hypertension, from KBP Biosciences in a deal worth up to $1.3bn.

Explore the last week